Organ Systems Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Organ Systems stocks.

Organ Systems Stocks Recent News

Date Stock Title
Feb 8 GMED Steris (STE) Lags Q3 Earnings and Revenue Estimates
Feb 8 ANVS Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 8 TERN Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice
Feb 8 BBIO Why 2023 is shaping up as a critical year for drug makers (Hint: It has something to do with cash)
Feb 8 ASRT Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know
Feb 8 ASRT Assertio to Participate in the 2023 SVB Securities Global Biopharma Conference
Feb 8 AVDL Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
Feb 8 ANVS Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Feb 8 BBIO BridgeBio Pharma to Participate in February and March Investor Events
Feb 5 SCLX Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
Feb 4 SCLX Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock
Feb 3 GMED Strength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?
Feb 2 GMED Globus Medical Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Feb 2 TERN Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
Feb 2 SCLX Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Feb 2 MLTX MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
Organ Systems

Browse All Tags